Titration of Medications after Acute Heart Failure is Safe, Tolerated, and Effective Regardless of Risk.

guideline-directed medical therapy heart failure outcomes risk stratification titration

Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
30 Apr 2024
Historique:
received: 30 01 2024
revised: 26 04 2024
accepted: 26 04 2024
medline: 13 5 2024
pubmed: 13 5 2024
entrez: 13 5 2024
Statut: aheadofprint

Résumé

Guideline-directed medical therapy decisions may be less affected by single patient variables such as blood pressure or kidney function and more by overall risk profile. In STRONG-HF, high intensity care (HIC) in the form of rapid uptitration of heart failure (HF) guideline-directed medical therapy (GDMT) was effective overall, but the safety, tolerability and efficacy of HIC across the spectrum of HF severity is unknown. Evaluating this with a simple risk-based framework offers an alternative and more clinically translatable approach than traditional subgroup analyses. To assess safety, tolerability, and efficacy of HIC according to the simple, powerful, and clinically translatable Meta-Analysis Global Group in Chronic (MAGGIC) HF risk score. In STRONG-HF, 1078 patients with acute HF were randomized to HIC (uptitration of treatments to 100% of recommended doses within 2 weeks of discharge and 4 scheduled outpatient visits over the 2 months after discharge) versus usual care (UC). The primary endpoint was the composite of all-cause death or first HF rehospitalization at Day 180. Baseline HF risk profile was determined by the previously validated MAGGIC risk score. Treatment effect was stratified according to MAGGIC risk score both as a categorical and continuous variable. Among 1062 patients (98.5%) with complete data for whom a MAGGIC score could be calculated at baseline, GDMT use at baseline was similar across MAGGIC tertiles. Overall GDMT prescriptions achieved for individual medication classes were higher in the HIC versus UC group and did not differ by MAGGIC risk score tertiles (interaction non-significant). The incidence of all-cause death or HF readmission at Day 180 was, respectively, 16.3%, 18.9%, and 23.2% for MAGGIC risk score tertiles 1-3. The HIC arm was at lower risk of all-cause death or HF readmission at Day 180 (HR 0.66, 95% CI 0.50-0.86) and this finding was robust across MAGGIC risk score modeled as a categorical (HR 0.51, 0.62, 0.68 in tertile 1, 2, and 3, respectively, (interaction non-significant) for all comparisons) and continuous (p-interaction=NS) variable. The rate of adverse events was higher in the HIC group, but this observation did not differ based on MAGGIC risk score tertile (interaction non-significant). HIC led to better use of GDMT and lower HF-related morbidity and mortality compared to UC regardless of underlying HF risk profile.

Sections du résumé

BACKGROUND BACKGROUND
Guideline-directed medical therapy decisions may be less affected by single patient variables such as blood pressure or kidney function and more by overall risk profile. In STRONG-HF, high intensity care (HIC) in the form of rapid uptitration of heart failure (HF) guideline-directed medical therapy (GDMT) was effective overall, but the safety, tolerability and efficacy of HIC across the spectrum of HF severity is unknown. Evaluating this with a simple risk-based framework offers an alternative and more clinically translatable approach than traditional subgroup analyses.
OBJECTIVES OBJECTIVE
To assess safety, tolerability, and efficacy of HIC according to the simple, powerful, and clinically translatable Meta-Analysis Global Group in Chronic (MAGGIC) HF risk score.
METHODS METHODS
In STRONG-HF, 1078 patients with acute HF were randomized to HIC (uptitration of treatments to 100% of recommended doses within 2 weeks of discharge and 4 scheduled outpatient visits over the 2 months after discharge) versus usual care (UC). The primary endpoint was the composite of all-cause death or first HF rehospitalization at Day 180. Baseline HF risk profile was determined by the previously validated MAGGIC risk score. Treatment effect was stratified according to MAGGIC risk score both as a categorical and continuous variable.
RESULTS RESULTS
Among 1062 patients (98.5%) with complete data for whom a MAGGIC score could be calculated at baseline, GDMT use at baseline was similar across MAGGIC tertiles. Overall GDMT prescriptions achieved for individual medication classes were higher in the HIC versus UC group and did not differ by MAGGIC risk score tertiles (interaction non-significant). The incidence of all-cause death or HF readmission at Day 180 was, respectively, 16.3%, 18.9%, and 23.2% for MAGGIC risk score tertiles 1-3. The HIC arm was at lower risk of all-cause death or HF readmission at Day 180 (HR 0.66, 95% CI 0.50-0.86) and this finding was robust across MAGGIC risk score modeled as a categorical (HR 0.51, 0.62, 0.68 in tertile 1, 2, and 3, respectively, (interaction non-significant) for all comparisons) and continuous (p-interaction=NS) variable. The rate of adverse events was higher in the HIC group, but this observation did not differ based on MAGGIC risk score tertile (interaction non-significant).
CONCLUSIONS CONCLUSIONS
HIC led to better use of GDMT and lower HF-related morbidity and mortality compared to UC regardless of underlying HF risk profile.

Identifiants

pubmed: 38739123
pii: S2213-1779(24)00337-8
doi: 10.1016/j.jchf.2024.04.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Andrew P Ambrosy (AP)

Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA; Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. Electronic address: andrew.p.ambrosy@kp.org.

Alex J Chang (AJ)

Department of Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.

Beth Davison (B)

Université Paris Cité, INSERM UMR-S 942(MASCOT), Paris, France; Momentum Research Inc, Durham, NC, USA; Heart Initiative, Durham, NC, USA.

Adriaan Voors (A)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

Alain Cohen-Solal (A)

Université Paris Cité, INSERM UMR-S 942(MASCOT), Paris, France; Department of Cardiology, APHP Nord, Lariboisière University Hospital, Paris, France.

Albertino Damasceno (A)

Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

Antoine Kimmoun (A)

Université de Lorraine, Nancy; INSERM, Défaillance Circulatoire Aigue et Chronique; Service de Médecine Intensive et Réanimation Brabois, CHRU de Nancy, 54511 Vandoeuvre-lès-Nancy, France.

Carolyn S P Lam (CSP)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands; National Heart Centre Singapore and Duke-National University of Singapore.

Christopher Edwards (C)

Momentum Research Inc, Durham, NC, USA.

Daniela Tomasoni (D)

Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Etienne Gayat (E)

Université Paris Cité, INSERM UMR-S 942(MASCOT), Paris, France; Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis and Lariboisière Hospitals, FHU PROMICE, DMU Parabol, APHP.Nord, Paris, France.

Gerasimos Filippatos (G)

National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.

Hadiza Saidu (H)

Murtala Muhammed Specialist Hospital / Bayero University Kano, Kano, Nigeria.

Jan Biegus (J)

Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.

Jelena Celutkiene (J)

Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Jozine M Ter Maaten (JM)

Department of Cardiology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

Kamilė Čerlinskaitė-Bajorė (K)

Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.

Karen Sliwa (K)

Cape Heart Institute, Department of Medicine and Cardiology, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.

Koji Takagi (K)

Momentum Research Inc, Durham, NC, USA.

Marco Metra (M)

Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Maria Novosadova (M)

Momentum Research Inc, Durham, NC, USA.

Marianela Barros (M)

Momentum Research Inc, Durham, NC, USA.

Marianna Adamo (M)

Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Matteo Pagnesi (M)

Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Mattia Arrigo (M)

Department of Internal Medicine, Stadtspital Zurich, Zurich, Switzerland.

Ovidiu Chioncel (O)

Emergency Institute for Cardiovascular Diseases "Prof. C.C.Iliescu", University of Medicine "Carol Davila," Bucharest, Romania.

Rafael Diaz (R)

Estudios Clínicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina.

Peter S Pang (PS)

Department of Emergency Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Piotr Ponikowski (P)

Institute of Heart Diseases, Wroclaw Medical University, Wrocław, Poland.

Gad Cotter (G)

Université Paris Cité, INSERM UMR-S 942(MASCOT), Paris, France; Momentum Research Inc, Durham, NC, USA; Heart Initiative, Durham, NC, USA.

Alexandre Mebazaa (A)

Université Paris Cité, INSERM UMR-S 942(MASCOT), Paris, France; Department of Anesthesiology and Critical Care and Burn Unit, Saint-Louis and Lariboisière Hospitals, FHU PROMICE, DMU Parabol, APHP.Nord, Paris, France.

Classifications MeSH